Jubilant Pharma establishes dollar curve

By Addison Gong
30 Sep 2016

Debut issuer Jubilant Pharma ventured out to the international bond market on September 29, netting $300m from its first dollar-denominated transaction.

The Indian generic drugs producer launched its five year non-call three via joint global co-ordinators, joint bookrunners and joint lead managers Citi, Credit Suisse, DBS, HSBC and JP Morgan, with initial price guidance set in the 5.25% area.

The last time an Indian pharma company came to the ...

Already a subscriber?

Continue reading this article

Try full access to GlobalCapital

Free trial